Barclays’s Amphastar Pharmaceuticals AMPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $417K | Sell |
21,283
-54,036
| -72% | -$1.32M | ﹤0.01% | 3292 |
|
|
2025
Q4 | $2.02M | Buy |
75,319
+8,825
| +13% | +$227K | ﹤0.01% | 2930 |
|
|
2025
Q3 | $1.77M | Sell |
66,494
-15,593
| -19% | -$403K | ﹤0.01% | 2966 |
|
|
2025
Q2 | $1.88M | Buy |
82,087
+15,135
| +23% | +$376K | ﹤0.01% | 2893 |
|
|
2025
Q1 | $1.94M | Sell |
66,952
-17,838
| -21% | -$570K | ﹤0.01% | 2657 |
|
|
2024
Q4 | $3.15M | Buy |
84,790
+10,334
| +14% | +$473K | ﹤0.01% | 2544 |
|
|
2024
Q3 | $3.61M | Buy |
74,456
+25,878
| +53% | +$1.14M | ﹤0.01% | 2359 |
|
|
2024
Q2 | $1.94M | Sell |
48,578
-22,254
| -31% | -$922K | ﹤0.01% | 2176 |
|
|
2024
Q1 | $3.11M | Buy |
70,832
+7,590
| +12% | +$392K | ﹤0.01% | 2195 |
|
|
2023
Q4 | $3.91M | Buy |
63,242
+39,449
| +166% | +$2.07M | ﹤0.01% | 2336 |
|
|
2023
Q3 | $1.09M | Sell |
23,793
-6,464
| -21% | -$353K | ﹤0.01% | 2270 |
|
|
2023
Q2 | $1.74M | Sell |
30,257
-11,057
| -27% | -$490K | ﹤0.01% | 1970 |
|
|
2023
Q1 | $1.55M | Sell |
41,314
-21,616
| -34% | -$709K | ﹤0.01% | 2396 |
|
|
2022
Q4 | $1.76M | Buy |
62,930
+7,426
| +13% | +$216K | ﹤0.01% | 2347 |
|
|
2022
Q3 | $1.56M | Sell |
55,504
-8,614
| -13% | -$281K | ﹤0.01% | 1914 |
|
|
2022
Q2 | $2.23M | Buy |
64,118
+11,773
| +22% | +$420K | ﹤0.01% | 1786 |
|
|
2022
Q1 | $1.88M | Sell |
52,345
-21,085
| -29% | -$598K | ﹤0.01% | 1907 |
|
|
2021
Q4 | $1.71M | Buy |
73,430
+9,613
| +15% | +$197K | ﹤0.01% | 2484 |
|
|
2021
Q3 | $1.21M | Buy |
63,817
+18,131
| +40% | +$355K | ﹤0.01% | 2661 |
|
|
2021
Q2 | $921K | Sell |
45,686
-29,431
| -39% | -$555K | ﹤0.01% | 2707 |
|
|
2021
Q1 | $1.38M | Buy |
75,117
+2,229
| +3% | +$41.4K | ﹤0.01% | 2567 |
|
|
2020
Q4 | $1.47M | Buy |
72,888
+4,109
| +6% | +$80K | ﹤0.01% | 2488 |
|
|
2020
Q3 | $1.29M | Buy |
68,779
+12,711
| +23% | +$256K | ﹤0.01% | 2470 |
|
|
2020
Q2 | $1.26M | Buy |
56,068
+12,793
| +30% | +$234K | ﹤0.01% | 2546 |
|
|
2020
Q1 | $642K | Sell |
43,275
-11,686
| -21% | -$203K | ﹤0.01% | 3377 |
|
|
2019
Q4 | $1.06M | Buy |
54,961
+17,564
| +47% | +$337K | ﹤0.01% | 3626 |
|
|
2019
Q3 | $742K | Sell |
37,397
-4,004
| -10% | -$83.4K | ﹤0.01% | 3923 |
|
|
2019
Q2 | $873K | Buy |
41,401
+10,352
| +33% | +$216K | ﹤0.01% | 3827 |
|
|
2019
Q1 | $634K | Buy |
31,049
+17,733
| +133% | +$397K | ﹤0.01% | 3887 |
|
|
2018
Q4 | $265K | Sell |
13,316
-24,796
| -65% | -$489K | ﹤0.01% | 4374 |
|
|
2018
Q3 | $733K | Buy |
38,112
+19,823
| +108% | +$353K | ﹤0.01% | 3932 |
|
|
2018
Q2 | $278K | Buy |
18,289
+759
| +4% | +$13.3K | ﹤0.01% | 4442 |
|
|
2018
Q1 | $328K | Buy |
17,530
+11,746
| +203% | +$221K | ﹤0.01% | 4379 |
|
|
2017
Q4 | $112K | Buy |
5,784
+4,942
| +587% | +$92.3K | ﹤0.01% | 5152 |
|
|
2017
Q3 | $15K | Sell |
842
-5,026
| -86% | -$82.7K | ﹤0.01% | 5923 |
|
|
2017
Q2 | $105K | Buy |
5,868
+1,871
| +47% | +$29.7K | ﹤0.01% | 4863 |
|
|
2017
Q1 | $59K | Sell |
3,997
-83,695
| -95% | -$1.32M | ﹤0.01% | 5236 |
|
|
2016
Q4 | $1.61M | Buy |
87,692
+47,590
| +119% | +$926K | ﹤0.01% | 2303 |
|
|
2016
Q3 | $760K | Buy |
40,102
+34,249
| +585% | +$622K | ﹤0.01% | 2887 |
|
|
2016
Q2 | $94K | Buy |
5,853
+3,146
| +116% | +$44.4K | ﹤0.01% | 4441 |
|
|
2016
Q1 | $33K | Buy |
2,707
+1,997
| +281% | +$23.5K | ﹤0.01% | 4995 |
|
|
2015
Q4 | $9K | Sell |
710
-13,442
| -95% | -$178K | ﹤0.01% | 5425 |
|
|
2015
Q3 | $156K | Buy |
14,152
+13,452
| +1,922% | +$202K | ﹤0.01% | 4306 |
|
|
2015
Q2 | $12K | Sell |
700
-84
| -11% | -$1.31K | ﹤0.01% | 5987 |
|
|
2015
Q1 | $11K | Buy |
784
+58
| +8% | +$775 | ﹤0.01% | 6165 |
|
|
2014
Q4 | $8K | Buy |
+726
| New | +$7.91K | ﹤0.01% | 6818 |
|
Other funds holding AMPH
VCM
BTW
Barclays's AMPH Position: Q1 2026 in Review
Barclays reduced its Amphastar Pharmaceuticals (AMPH) stake by 72% in Q1 2026, selling an estimated $1.32M and leaving 21,283 shares worth $417K. The position accounts for ﹤0.01% of the portfolio, ranked #3292.
Barclays first reported a position in AMPH in Q4 2014 and has held it in 46 quarters since. The position peaked at $3.91M in Q4 2023. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.
- Barclays held 21,283 shares of Amphastar Pharmaceuticals worth $417K as of Q1 2026.
- Barclays sold 54,036 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $1.32M.
- Amphastar Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3292 holding.
- Barclays first reported a position in Amphastar Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
- Barclays's Amphastar Pharmaceuticals position peaked at $3.91M in Q4 2023.
- 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.